DK1242822T3 - Fremgangsmåder til påvisning af amyloidogene proteiner - Google Patents

Fremgangsmåder til påvisning af amyloidogene proteiner

Info

Publication number
DK1242822T3
DK1242822T3 DK00980905T DK00980905T DK1242822T3 DK 1242822 T3 DK1242822 T3 DK 1242822T3 DK 00980905 T DK00980905 T DK 00980905T DK 00980905 T DK00980905 T DK 00980905T DK 1242822 T3 DK1242822 T3 DK 1242822T3
Authority
DK
Denmark
Prior art keywords
aggregation
assay
amyloid
peptide
amyloid peptide
Prior art date
Application number
DK00980905T
Other languages
English (en)
Inventor
Girija Krishnamurthy
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Application granted granted Critical
Publication of DK1242822T3 publication Critical patent/DK1242822T3/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK00980905T 1999-12-29 2000-12-01 Fremgangsmåder til påvisning af amyloidogene proteiner DK1242822T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/474,970 US6399314B1 (en) 1999-12-29 1999-12-29 Methods of detection of amyloidogenic proteins
PCT/US2000/032693 WO2001050134A2 (en) 1999-12-29 2000-12-01 Methods of detection of amyloidogenic proteins

Publications (1)

Publication Number Publication Date
DK1242822T3 true DK1242822T3 (da) 2008-09-29

Family

ID=23885720

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00980905T DK1242822T3 (da) 1999-12-29 2000-12-01 Fremgangsmåder til påvisning af amyloidogene proteiner

Country Status (21)

Country Link
US (1) US6399314B1 (da)
EP (1) EP1242822B1 (da)
JP (1) JP2003519383A (da)
KR (1) KR20020070470A (da)
CN (1) CN1211661C (da)
AT (1) ATE399323T1 (da)
AU (1) AU774377B2 (da)
BR (1) BR0016883A (da)
CA (1) CA2395789C (da)
DE (1) DE60039310D1 (da)
DK (1) DK1242822T3 (da)
EA (1) EA005582B1 (da)
ES (1) ES2309003T3 (da)
HK (1) HK1046550B (da)
IL (2) IL150080A0 (da)
MX (1) MXPA02006362A (da)
NO (1) NO20023163L (da)
NZ (1) NZ519612A (da)
PL (1) PL356813A1 (da)
PT (1) PT1242822E (da)
WO (1) WO2001050134A2 (da)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6750324B1 (en) 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US6913745B1 (en) 1997-12-02 2005-07-05 Neuralab Limited Passive immunization of Alzheimer's disease
US6761888B1 (en) * 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US7179892B2 (en) * 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US6787523B1 (en) 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7964192B1 (en) * 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US6905686B1 (en) 1997-12-02 2005-06-14 Neuralab Limited Active immunization for treatment of alzheimer's disease
US20030147882A1 (en) * 1998-05-21 2003-08-07 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
DE19923811C1 (de) * 1999-05-20 2000-12-07 Robert Koch Inst Verfahren zur Diagnose TSE-induzierter Veränderungen in Geweben mittels Infrarotspektroskopie
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
US6689753B1 (en) * 1999-11-05 2004-02-10 Axonyx, Inc. β sheet breaker peptide analogs that inhibit β pleated sheet formation in amyloid β-peptide
EP1322959A1 (en) 2000-08-21 2003-07-02 The General Hospital Corporation Methods for diagnosing a neurodegenerative condition
PE20020574A1 (es) * 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
JP2005511498A (ja) * 2001-04-27 2005-04-28 ザ・ブリガム・アンド・ウイメンズ・ホスピタル・インコーポレイテッド アルツハイマー病の視覚診断
US7166471B2 (en) * 2001-05-31 2007-01-23 Arete Associates Misfolded protein sensor method in body fluids
US20050026165A1 (en) * 2001-05-31 2005-02-03 Cindy Orser Detection of conformationally altered proteins and prions
US20060057107A1 (en) * 2001-12-21 2006-03-16 Shaked Ze Ev Combination treatment for multiple sclerosis
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
US20070003552A1 (en) * 2002-07-09 2007-01-04 Gebbink Martijn F B Cross-beta structure comprising amyloid binding proteins and methods for detection of the cross-beta structure, for modulating cross-beta structures fibril formation and for modulating cross-beta structure-mediated toxicity and method for interfering with blood coagulation
EP1380290A1 (en) * 2002-07-09 2004-01-14 Universitair Medisch Centrum Utrecht Cross-beta structure pathway and its therapeutic relevance
TWI306458B (en) 2003-05-30 2009-02-21 Elan Pharma Int Ltd Humanized antibodies that recognize beta amyloid peptide
US20050048539A1 (en) * 2003-06-13 2005-03-03 The General Hospital Corporation Methods to monitor molecule conformation and molecule/molecule proximity
SE0401219D0 (sv) * 2004-05-10 2004-05-10 Biochromix Ab Metoder för detektera konformationsförändringar eller aggregering hos proteiner med hjälp av konjugerade polyelektrolyter
US20060057671A1 (en) * 2004-09-10 2006-03-16 Orser Cindy S Immobilized probes and methods of detecting conformationally altered prion proteins
WO2006066171A1 (en) * 2004-12-15 2006-06-22 Neuralab Limited Amyloid βετα antibodies for use in improving cognition
EP1838854B1 (en) * 2004-12-15 2012-10-31 Janssen Alzheimer Immunotherapy Antibodies that recognize Beta Amyloid Peptide
CA2590337C (en) 2004-12-15 2017-07-11 Neuralab Limited Humanized amyloid beta antibodies for use in improving cognition
JP4568840B2 (ja) * 2004-12-28 2010-10-27 国立大学法人金沢大学 アルツハイマー病の検査方法
WO2006069697A1 (en) * 2004-12-30 2006-07-06 F. Hoffmann-La Roche Ag Colorimetrically assessing peptide characteristics
MX2007009819A (es) * 2005-02-15 2007-11-07 Adlyfe Inc Metodo para detectar proteinas y priones desplegados.
US20090202980A1 (en) * 2005-03-21 2009-08-13 Crossbeta Biosciences B.V. Cross-Beta Structure Comprising Amyloid Binding Proteins and Methods for Detection of the Cross-Beta Structure, for Modulating Cross-Beta Structures Fibril Formation and for Modulating Cross-Beta Structure-Mediated Toxicity and Method for Interfering With Blood Coagulation
EP1906995A2 (en) * 2005-07-13 2008-04-09 Crossbeta Biosciences B.V. Adjuvation through cross- structure
US20070015133A1 (en) * 2005-07-13 2007-01-18 Umc Utrecht Holding B.V. Method for detecting and/or removing protein and/or peptide comprising a cross-beta structure from an aqueous solution comprising a protein
CA2615028A1 (en) * 2005-07-13 2007-01-18 Crossbeta Biosciences B.V. Cross-.beta. structure binding compounds
US8114832B2 (en) * 2005-07-13 2012-02-14 Crossbeta Biosciences B.V. Method for detecting and/or removing a protein comprising a cross-beta structure from a pharmaceutical composition
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
EP2156181B1 (en) * 2006-07-28 2015-11-04 Adlyfe, Inc. Peptide probes for diagnostics and therapeutics
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
ES2498040T3 (es) 2007-07-27 2014-09-24 Janssen Alzheimer Immunotherapy Tratamiento de enfermedades amiloidogénicas con anticuerpos anti-beta humanizados
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
EP2058001A1 (en) * 2007-11-08 2009-05-13 Crossbeta Biosciences B.V. Enhancement of immunogenicity of antigens
EP2058000A1 (en) * 2007-11-08 2009-05-13 Crossbeta Biosciences B.V. Immunogenic compositions capable of activating T cells
US20100021390A1 (en) * 2008-03-17 2010-01-28 The Research Foundation Of State University Of New York Fluorescent Analogs Of The Islet Amyloid Polypeptide
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
RU2509155C1 (ru) * 2012-10-25 2014-03-10 Федеральное государственное бюджетное учреждение науки Институт биохимии им. А.Н. Баха Российской академии наук Способ детекции белков в амилоидном состоянии и набор для детекции белков в амилоидном состоянии
GB201303507D0 (en) * 2013-02-27 2013-04-10 Hollfelder Florian Assays
US9588129B2 (en) * 2013-03-15 2017-03-07 Amira Medical Technologies Inc. Methods for analyzing blood to detect diseases associated with abnormal protein aggregation
CN104803993B (zh) * 2015-03-01 2017-11-03 四川大学 一种具有Aβ亲和力的荧光化合物及其用途
CN105651752B (zh) * 2016-02-26 2019-04-12 国家纳米科学中心 淀粉样蛋白的检测方法
CN105717182B (zh) * 2016-03-10 2018-05-11 中南大学 一种用于同步检测淀粉样多肽单体和聚集体的生物传感器及其构建方法和应用
US11536731B2 (en) 2017-01-23 2022-12-27 Rensselaer Polytechnic Institute Systems and methods for binding amyloid fibrils using fluorescent protein
CN108489941B (zh) * 2018-01-31 2021-07-27 吉林大学 溴酚蓝在作为检测牛胰岛素淀粉样纤维探针和作为牛胰岛素淀粉样纤维抑制剂方面的应用
US20210165001A1 (en) * 2018-08-03 2021-06-03 The University Of Hong Kong Compositions and methods for detection and imaging of amyloid fibrils, amyloid plaques, rna, and nucleoli
CN111504957B (zh) * 2019-01-31 2021-12-03 吉林大学 一种维多利亚蓝b及其衍生物在制备异构化蛋白的探针或抑制剂中的应用
KR102258048B1 (ko) * 2019-05-30 2021-05-31 주식회사 캔티스 아밀로이드 베타 올리고머의 검출 방법

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2013396A1 (en) * 1989-04-05 1990-10-05 Dennis J. Selkoe Diagnostic method for alzheimer's disease: examination of non-neural tissue
US5276059A (en) 1992-07-10 1994-01-04 The United States Of America As Represented By The Department Of Health And Human Services Inhibition of diseases associated with amyloid formation
AU6728396A (en) 1995-08-17 1997-03-12 Ontario Cancer Institute, The Protein fibril assembly assay
JPH0995444A (ja) * 1995-10-02 1997-04-08 Teijin Ltd アミロイド蛋白凝集阻害剤
EP1003539A4 (en) 1997-08-14 2002-09-11 Univ California AMYLOID beta-FLUORESCENT PEPTIDES AND USE THEREOF
AU3083899A (en) * 1998-03-13 1999-09-27 University Of Washington (in vitro) formation of congophilic maltese-cross amyloid plaques to identify anti-plaque therapeutics for the treatment of alzheimer's and prion diseases

Also Published As

Publication number Publication date
HK1046550A1 (en) 2003-01-17
ATE399323T1 (de) 2008-07-15
IL150080A (en) 2009-02-11
IL150080A0 (en) 2002-12-01
NZ519612A (en) 2004-04-30
CA2395789C (en) 2010-03-30
BR0016883A (pt) 2002-10-01
NO20023163L (no) 2002-08-27
HK1046550B (zh) 2008-12-19
AU1810301A (en) 2001-07-16
MXPA02006362A (es) 2002-11-29
EA005582B1 (ru) 2005-04-28
JP2003519383A (ja) 2003-06-17
KR20020070470A (ko) 2002-09-09
NO20023163D0 (no) 2002-06-28
AU774377B2 (en) 2004-06-24
WO2001050134A3 (en) 2002-06-27
EP1242822A2 (en) 2002-09-25
CA2395789A1 (en) 2001-07-12
PT1242822E (pt) 2008-09-29
US6399314B1 (en) 2002-06-04
DE60039310D1 (de) 2008-08-07
EA200200722A1 (ru) 2002-12-26
ES2309003T3 (es) 2008-12-16
EP1242822B1 (en) 2008-06-25
CN1211661C (zh) 2005-07-20
CN1415074A (zh) 2003-04-30
WO2001050134A2 (en) 2001-07-12
PL356813A1 (en) 2004-07-12

Similar Documents

Publication Publication Date Title
DK1242822T3 (da) Fremgangsmåder til påvisning af amyloidogene proteiner
Jeong et al. Real-time monitoring of glutathione in living cells reveals that high glutathione levels are required to maintain stem cell function
DK0679251T3 (da) Fremgangsmåde og apparat til vurdering af biopolymerers fitness
Strucksberg et al. Proteasomal activity in skeletal muscle: a matter of assay design, muscle type, and age
ATE443775T1 (de) Hif-prolylhydroxylase-aktivitätstest
HK1124117A1 (en) Analysis system for analysing a sample on an analytical test element
ES2422295T3 (es) Aparato y procedimiento para la concentración y representación de partículas de ensayo
TW200632320A (en) Methods of in vitro analysis using time-domain nmr spectroscopy
BRPI0812875B8 (pt) " método in vitro para indentificar se ou não um indivíduo está sob risco de desenvolvimento de sépsis severa, e, kit de teste
EP3851856A3 (en) Method, array and use thereof
ATE525656T1 (de) Proteinmessverfahren
AR071034A1 (es) Uso de la catepsina c en el diagnostico de susceptibilidad al dolor y para el tratamiento del dolor
ATE410677T1 (de) Bioäquivalenztest für eisenhaltige formulierungen
FR2894675B1 (fr) Distinction des meningites bacteriennes et virales
WO2002066982A8 (de) Analyse von modifizierungen und demodifizierungen von proteinen mit ubiquintin-verwandten proteinen mittels fret (fluorescence resonance energy transfer)
JPH01210863A (ja) 精子細胞計数および生存精子細胞の比率、あるいは、これらいずれか一方の高速定量方法ならびにその装置
DE50214753D1 (de) Vorrichtung zur bestimmung rheologischer eigenschaften
DE602004026869D1 (de) Diagnose von leberzirrhose mittels eines für menschliches protoonkogenes protein spezifischen antikörpers
DE60324820D1 (de) Verfahren zum testen des oxidiertes-ldl-beta-2-glycoprotein-i-komplexes in vivo
DE60002466D1 (de) Quantifizierungsverfahren für endotheliale mikroteilchen
RU2008132559A (ru) Способ оценки агрегационной способности эритроцитов
DE602004021193D1 (de) Erstellung von digitalaufnahmen einzelner radialer immundiffusionstests
Zangarelli et al. Centrifugation-based isolation of myosin for measurement of its synthesis rate in small muscle samples
Falamas et al. Monitoring the RNA distribution in human embryonic stem cells using Raman micro-spectroscopy and fluorescence imaging
FR2846009B1 (fr) Criblage de molecules a activite anti-prion:kits, methodes et molecules criblees